Loading clinical trials...
Loading clinical trials...
A Bioequivalence Study of Subcutaneous Injections of Mirikizumab Reference Solution Using Investigational 1-mL and 2-mL Prefilled Syringes and Mirikizumab Test Solution Formulation Using Investigational 1-mL and 2-mL Prefilled Syringes in Healthy Participants
Conditions
Interventions
Mirikizumab
Locations
6
United States
Altasciences Clinical Los Angeles, Inc
Cypress, California, United States
LabCorp CRU, Inc.
Daytona Beach, Florida, United States
Clinical Pharmacology of Miami
Miami, Florida, United States
Qps-Mra, Llc
Miami, Florida, United States
Axis
Dilworth, Minnesota, United States
Labcorp Clinical Research LP
Dallas, Texas, United States
Start Date
December 5, 2022
Primary Completion Date
May 25, 2023
Completion Date
May 25, 2023
Last Updated
March 28, 2025
NCT07310264
NCT06290258
NCT00090662
NCT06716502
NCT07483606
NCT06342713
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions